Search

Your search keyword '"Stephen C. Yang"' showing total 11 results
Start Over Author "Stephen C. Yang" Publisher harborside press, llc
11 results on '"Stephen C. Yang"'

1. NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023

Author

David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aparna Hegde, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Gregory J. Riely, Jonathan Riess, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, and Miranda Hughes

Subjects
Oncology
Abstract

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC. These NCCN Guidelines Insights focus on neoadjuvant and adjuvant (also known as perioperative) systemic therapy options for eligible patients with resectable NSCLC.

Published
2023
Full Text
View/download PDF

2. NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022

Author

Douglas E. Wood, Ella A. Kazerooni, Denise Aberle, Abigail Berman, Lisa M. Brown, Georgie A. Eapen, David S. Ettinger, J. Scott Ferguson, Lifang Hou, Dipen Kadaria, Donald Klippenstein, Rohit Kumar, Rudy P. Lackner, Lorriana E. Leard, Inga T. Lennes, Ann N.C. Leung, Peter Mazzone, Robert E. Merritt, David E. Midthun, Mark Onaitis, Sudhakar Pipavath, Christie Pratt, Varun Puri, Dan Raz, Chakravarthy Reddy, Mary E. Reid, Kim L. Sandler, Jacob Sands, Matthew B. Schabath, Jamie L. Studts, Lynn Tanoue, Betty C. Tong, William D. Travis, Benjamin Wei, Kenneth Westover, Stephen C. Yang, Beth McCullough, and Miranda Hughes

Subjects
Oncology
Abstract

The NCCN Guidelines for Lung Cancer Screening recommend criteria for selecting individuals for screening and provide recommendations for evaluation and follow-up of lung nodules found during initial and subsequent screening. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Lung Cancer Screening.

Published
2022
Full Text
View/download PDF

3. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

Author

Jessica Bauman, Alda Tam, Christine M. Lovly, Scott N. Gettinger, Daniel Morgensztern, Aditi P. Singh, Steven E. Schild, Miranda Hughes, Lucian R. Chirieac, Debora S. Bruno, Erminia Massarelli, Aparna Hegde, Renato Martins, Jane Yanagawa, Thomas Ng, Ankit Bharat, Billy W. Loo, Douglas E. Wood, Matthew A. Gubens, Theresa A. Shapiro, Mark Hennon, Gregory J. Riely, Gregory A. Otterson, James P. Stevenson, Rudy P. Lackner, Kristina M. Gregory, Joe Y. Chang, Dara L. Aisner, Jules Lin, Jonathan E. Dowell, Sandip P. Patel, Stephen C. Yang, Thomas A. D'Amico, Wallace Akerley, Thomas J. Dilling, David S. Ettinger, Michael Lanuti, and Ticiana A. Leal

Subjects
Oncology, medicine.medical_specialty, business.industry, medicine.disease, respiratory tract diseases, Clinical Practice, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, medicine, 030212 general & internal medicine, Non small cell, business, Lung cancer
Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.

Published
2021
Full Text
View/download PDF

4. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020

Author

Gregory J. Riely, Thomas A. D'Amico, Ticiana A. Leal, Leora Horn, Thomas J. Dilling, Renato Martins, Kurt Tauer, Debora S. Bruno, Charu Aggarwal, Steven E. Schild, Joe Y. Chang, Rudy P. Lackner, Matthew A. Gubens, Mark Hennon, Michael C. Dobelbower, Karen L. Reckamp, Miranda Hughes, David S. Ettinger, Michael Lanuti, James P. Stevenson, Theresa A. Shapiro, Scott J. Swanson, Ramaswamy Govindan, Scott N. Gettinger, Gregory A. Otterson, Jules Lin, Billy W. Loo, Stephen C. Yang, Dara L. Aisner, Sandip Pravin Patel, Ankit Bharat, Douglas E. Wood, Wallace Akerley, Jessica Bauman, Kristina M. Gregory, and Lucian R. Chirieac

Subjects
medicine.medical_specialty, Lung Neoplasms, business.industry, Psychological intervention, MEDLINE, Antineoplastic Agents, medicine.disease, Systemic therapy, respiratory tract diseases, Oncology, Carcinoma, Non-Small-Cell Lung, Practice Guidelines as Topic, medicine, Humans, Immunotherapy, Non small cell, Lung cancer, business, Intensive care medicine
Abstract

The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as “preferred interventions,” whereas others are categorized as either “other recommended interventions” or “useful under certain circumstances.”

Published
2019
Full Text
View/download PDF

5. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018

Author

Matthew A. Gubens, Theresa A. Shapiro, Douglas E. Wood, Gregory J. Riely, Lucian R. Chirieac, Karen L. Reckamp, Leora Horn, Renato G. Martins, Gregory A. Otterson, Michael C. Dobelbower, David S. Ettinger, Rudy P. Lackner, Kurt Tauer, Dara L. Aisner, Sandip Pravin Patel, Stephen C. Yang, Michael Lanuti, Kristina M. Gregory, James P. Stevenson, Scott J. Swanson, Ticiana A. Leal, Billy W. Loo, Jules Lin, Mark Hennon, Rogerio Lilenbaum, Miranda Hughes, Ramaswamy Govindan, Joe Y. Chang, Thomas A. D'Amico, Thomas J. Dilling, Steven E. Schild, Wallace Akerley, and Jessica Bauman

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Medical Oncology, Neoplasm genetics, Targeted therapy, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Medicine, Molecular Targeted Therapy, Progression-free survival, Lung cancer, Societies, Medical, Randomized Controlled Trials as Topic, business.industry, Disease progression, medicine.disease, Progression-Free Survival, United States, respiratory tract diseases, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Mutation, Disease Progression, Non small cell, business
Abstract

The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the targeted therapy and immunotherapy sections in the NCCN Guidelines. For the 2018 update, a new section on biomarkers was added.

Published
2018
Full Text
View/download PDF

6. Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

Author

Lucian R. Chirieac, Jessica Bauman, Thomas A. D'Amico, Thomas J. Dilling, Leah J. Leisch, Steven E. Schild, Ticiana A. Leal, Douglas E. Wood, Scott J. Swanson, Robert C. Doebele, Wallace Akerley, Renato Martins, James P. Stevenson, Mark Hennon, Leora Horn, Rogerio Lilenbaum, Malcolm M. DeCamp, Gregory A. Otterson, Dara L. Aisner, Kristina M. Gregory, Miranda Hughes, Karen L. Reckamp, Ramaswamy Govindan, Theresa A. Shapiro, Billy W. Loo, Matthew A. Gubens, Jules Lin, Gregory J. Riely, David S. Ettinger, Rudy P. Lackner, Kurt Tauer, Michael Lanuti, Ritsuko Komaki, Michael C. Dobelbower, and Stephen C. Yang

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Disease, Pembrolizumab, 03 medical and health sciences, 0302 clinical medicine, Recurrence, Atezolizumab, Carcinoma, Non-Small-Cell Lung, Internal medicine, Humans, Medicine, Combined Modality Therapy, Osimertinib, Molecular Targeted Therapy, Neoplasm Metastasis, Lung cancer, Clinical Trials as Topic, Ceritinib, business.industry, Disease Management, Immunotherapy, Prognosis, medicine.disease, respiratory tract diseases, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, business, Biomarkers, medicine.drug
Abstract

This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.

Published
2017
Full Text
View/download PDF

7. NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016

Author

Lyudmila Bazhenova, Thierry Jahan, Jyoti D. Patel, Scott J. Swanson, Ramaswamy Govindan, Jules Lin, Gregory A. Otterson, Kurt Tauer, Karen L. Reckamp, M. Chris Dobelbower, Thomas A. D'Amico, Lucian R. Chirieac, Wallace Akerley, Thomas J. Dilling, D.R. Camidge, Katherine M.W. Pisters, Stephen C. Yang, Michael Lanuti, James P. Stevenson, Neelesh Sharma, Mark Hennon, Rogerio Lilenbaum, Renato G. Martins, Miranda Hughes, Gregory J. Riely, David S. Ettinger, Leora Horn, Rudy P. Lackner, Steven E. Schild, Billy W. Loo, Richard T. Cheney, Theresa A. Shapiro, Kristina M. Gregory, Douglas E. Wood, Ritsuko Komaki, and Hossein Borghaei

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, business.industry, Pembrolizumab, medicine.disease, Surgery, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Docetaxel, 030220 oncology & carcinogenesis, Internal medicine, medicine, In patient, Non small cell, Nivolumab, Lung cancer, Adverse effect, business, Survival rate, medicine.drug
Abstract

These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.

Published
2016
Full Text
View/download PDF

8. Lung Cancer Screening, Version 1.2015

Author

Ann N. Leung, Ella A. Kazerooni, Douglas E. Wood, Bryan F. Meyers, David M. Jackman, Peter B. Sachs, Christie Pratt-Pozo, Chakravarthy Reddy, Georgie A. Eapen, Lifang Hou, Arnold J. Rotter, Rudy P. Lackner, Mary E. Reid, Matthew B. Schabath, Betty C. Tong, Kimberly S. Peairs, Mark T. Dransfield, Rohit Kumar, David S. Ettinger, William D. Travis, Scott Baum, Lecia V. Sequist, Stephen C. Yang, Lorriana E. Leard, Kristina M. Gregory, Gregory A. Otterson, Miranda Hughes, Pierre P. Massion, Donald Klippenstein, Sudhakar Pipavath, and Samir S. Makani

Subjects
medicine.medical_specialty, medicine.diagnostic_test, business.industry, MEDLINE, Computed tomography, respiratory system, Clinical Practice, Oncology, X ray computed, medicine, Medical physics, Radiology, business, Lung cancer screening
Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening provide recommendations for selecting individuals for lung cancer screening, and for evaluation and follow-up of nodules found during screening, and are intended to assist with clinical and shared decision-making. These NCCN Guidelines Insights focus on the major updates to the 2015 NCCN Guidelines for Lung Cancer Screening, which include a revision to the recommendation from category 2B to 2A for one of the high-risk groups eligible for lung cancer screening. For low-dose CT of the lung, the recommended slice width was revised in the table on "Low-Dose Computed Tomography Acquisition, Storage, Interpretation, and Nodule Reporting."

Published
2015
Full Text
View/download PDF

9. Non–Small Cell Lung Cancer, Version 1.2015

Author

Kristina M. Gregory, Gregory A. Otterson, Ramaswamy Govindan, Rogerio Lilenbaum, Miranda Hughes, Jules Lin, Scott J. Swanson, Steven E. Schild, Douglas E. Wood, Ritsuko Komaki, Renato G. Martins, Leora Horn, Katherine M.W. Pisters, Lucian R. Chirieac, Rudy P. Lackner, Frederic W. Grannis, Todd L. Demmy, Karen L. Reckamp, Kurt Tauer, Theresa A. Shapiro, Thomas A. D'Amico, Lee M. Krug, Thomas J. Dilling, Billy W. Loo, Eric M. Rohren, Michael Lanuti, David S. Ettinger, D.R. Camidge, Wallace Akerley, Hossein Borghaei, Lyudmila Bazhenova, Richard T. Cheney, Thierry Jahan, Stephen C. Yang, Gregory J. Riely, Mark G. Kris, and Jyoti D. Patel

Subjects
Oncology, medicine.medical_specialty, Lung Neoplasms, Palliative care, business.industry, medicine.medical_treatment, Palliative Care, Guidelines as Topic, medicine.disease, Combined Modality Therapy, Radiation therapy, Clinical Practice, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Carcinoma, Humans, Non small cell, Medical prescription, Lung cancer, business
Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) focuses on the principles of radiation therapy (RT), which include the following: (1) general principles for early-stage, locally advanced, and advanced/metastatic NSCLC; (2) target volumes, prescription doses, and normal tissue dose constraints for early-stage, locally advanced, and advanced/palliative RT; and (3) RT simulation, planning, and delivery. Treatment recommendations should be made by a multidisciplinary team, including board-certified radiation oncologists who perform lung cancer RT as a prominent part of their practice.

Published
2014
Full Text
View/download PDF

10. Non–Small Cell Lung Cancer, Version 2.2013

Author

Karen L. Reckamp, Mark G. Kris, Leora Horn, Katherine M.W. Pisters, Kurt Tauer, Wallace Akerley, Jyoti D. Patel, Lucian R. Chirieac, Stephen C. Yang, Hossein Borghaei, Rudy P. Lackner, Theresa A. Shapiro, Renato Martins, Gregory A. Otterson, Ritsuko Komaki, Lee M. Krug, Inga T. Lennes, Miranda Hughes, Mary Pinder-Schenck, Richard T. Cheney, Billy W. Loo, Ramaswamy Govindan, Feng Ming Kong, Scott J. Swanson, Kristina M. Gregory, Frederic W. Grannis, Stefan C. Grant, Eric M. Rohren, Douglas E. Wood, Thomas A. D'Amico, Andrew C. Chang, Todd L. Demmy, David S. Ettinger, Thierry Jahan, and Gregory J. Riely

Subjects
medicine.medical_specialty, Lung Neoplasms, business.industry, Diagnostic evaluation, medicine.disease, Clinical Practice, Oncology, Carcinoma, Non-Small-Cell Lung, medicine, Humans, Medical physics, Non small cell, Suspected lung cancer, business, Lung cancer
Abstract

These NCCN Guidelines Insights focus on the diagnostic evaluation of suspected lung cancer. This topic was the subject of a major update in the 2013 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer. The NCCN Guidelines Insights focus on the major updates in the NCCN Guidelines and discuss the new updates in greater detail.

Published
2013
Full Text
View/download PDF

11. Lung Cancer Screening

Author

Douglas E. Wood, Chakravarthy Reddy, Arnold J. Rotter, Reginald F. Munden, Bryan F. Meyers, Matthew B. Schabath, David M. Jackman, Betty C. Tong, Pierre P. Massion, Mary E. Reid, Lifang Hou, Donald Klippenstein, David S. Ettinger, Sudhakar Pipavath, Christie Pratt-Pozo, Lorriana E. Leard, Ella A. Kazerooni, Kimberly S. Peairs, Rudy P. Lackner, George A. Eapen, Lecia V. Sequist, Ann N. Leung, William D. Travis, Gregory A. Otterson, Stephen C. Yang, and Michael Unger

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, MEDLINE, Psychological intervention, medicine.disease, Oncology, Cohort, Medicine, Smoking cessation, Observational study, Medical physics, business, Lung cancer, Intensive care medicine, Pulmonologists, Lung cancer screening
Abstract

Lung cancer screening with LDCT is a complex and controversial topic, with inherent risks and benefits. Results from the large, prospective, randomized NLST show that lung cancer screening with LDCT can decrease lung cancer–specific mortality by 20% and even decrease all-cause mortality by 7%.8 The NLST results indicate that to prevent one death from lung cancer, 320 high-risk individuals must be screened with LDCT. However, the NLST findings have not been replicated yet in a separate cohort. Further analysis of the NLST is underway, including comparative effectiveness modeling. The cost-effectiveness and true benefit-to-risk ratio for lung cancer screening still must be determined. At some point, an acceptable level of risk will have to be deemed appropriate for the benefits of screening. The NCCN Lung Cancer Screening Panel recommends helical LDCT screening for select patients at high risk for lung cancer based on the NLST results, nonrandomized studies, and observational data. These guidelines discuss in detail the criteria for determining which patients are at high risk, and the algorithm provides recommendations for evaluating and following-up nodules detected on LDCT screening (e.g., solid and part-solid nodules). Smokers should always be encouraged to quit smoking tobacco (http://www.smokefree.gov/). Programs using behavioral counseling combined with medications that promote smoking cessation (approved by the FDA) can be very useful (see Treating Tobacco Use and Dependence: Quick Reference Guide for Clinicians; http://www.surgeongeneral.gov/tobacco/tobaqrg.htm). When considering lung cancer screening, it is important to have a full understanding of all risks and benefits related to screening with LDCT. As policies for implementing lung screening programs are designed, a focus on multidisciplinary programs (incorporating primary care doctors, pulmonologists, radiologists, thoracic surgeons, medical oncologists, and pathologists) will be helpful to optimize decision-making and minimize interventions for patients with benign lung disease.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results